JAZZ 28$

Jazz Pharmaceuticals Announces Fourth Quarter And Full Year 2010 Results

Quote:

Quote

– Fourth quarter net product sales grow to $52.4 million –

– Guidance for 2011 adjusted earnings per diluted share in range of $2.70 – $2.90; 2011 GAAP earnings per diluted share expected to be $2.22 – $2.41

PALO ALTO, Calif., March 7, 2011 /PRNewswire/ –Jazz Pharmaceuticals, Inc. (JAZZ: 27.30 +0.19 +0.70%) today announced financial results for the fourth quarter and full year ended December 31, 2010.

Total revenues for the fourth quarter of 2010 were $53.4 million, compared to $38.3 million for the fourth quarter of 2009. Full year 2010 revenues were $173.8 million, up 35 percent compared to revenues of $128.4 million for 2009.

GAAP net income for the fourth quarter of 2010 was $24.5 million, or $0.56 per diluted share, compared to $5.7 million, or $0.17 per diluted share, for the fourth quarter of 2009. GAAP net income for 2010 was $32.8 million, or $0.83 per diluted share, compared to a 2009 GAAP net loss of $6.8 million, or $0.23 per diluted share.

Adjusted net income for the fourth quarter of 2010 was $27.2 million, or $0.63 per diluted share, compared to $10.8 million, or $0.33 per diluted share, for the fourth quarter of 2009. Adjusted net income for 2010 was $61.0 million, or $1.55 per diluted share, compared to a 2009 adjusted net loss of $1.5 million, or $0.05 per diluted share. A reconciliation of GAAP net income (loss) to adjusted net income (loss) and the related per diluted share amounts is included with this press release.

Net sales of Xyrem® (sodium oxybate) oral solution increased 36 percent to $42.9 million for the fourth quarter of 2010, compared to net sales of $31.6 million for the fourth quarter of 2009. Xyrem net sales for 2010 increased 47 percent to $142.6 million, compared to $96.8 million in net sales for 2009. Net sales of once-daily Luvox CR® (fluvoxamine maleate) increased to $9.4 million for the fourth quarter of 2010, compared to $5.7 million for the fourth quarter of 2009. Luvox CR net sales for 2010 increased to $27.4 million, compared to 2009 net sales of $18.3 million. Both fourth quarter and full year 2010 net sales of Luvox CR include $2.0 million of revenue recorded as a result of a change in the timing of when revenue is recognized; the company now records Luvox CR sales upon shipment to distributors net of estimated returns. The profit associated with this change has been excluded from the company’s fourth quarter and full year 2010 adjusted net income.

“In 2010, our first full year of profitability, our progress included strengthening our balance sheet, enhancing our commercial business management team, significantly increasing Xyrem sales, and broadening our patent protection for sodium oxybate,” said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. ”We look forward to improving our performance in 2011, as we continue to grow and protect our Xyrem business and advance our intranasal clonazepam product candidate for acute repetitive seizures in epilepsy patients.”

Research and development expenses for the fourth quarter of 2010 were $4.1 million, compared to $6.3 million for the fourth quarter of 2009. Research and development expenses in 2010 were $25.6 million, compared to $36.6 million for 2009.

Selling, general and administrative expenses for the fourth quarter of 2010 were $17.1 million, compared to $15.7 million for the fourth quarter of 2009. In 2010, selling, general and administrative expenses were $69.0 million, compared to $58.7 million for 2009.

Interest expense for the fourth quarter of 2010 was $1.1 million, compared to $5.8 million for the prior year period. Interest expense in 2010 was $12.7 million, compared to $22.8 million in 2009. As of December 31, 2010, cash and cash equivalents were $44.8 million, an increase from $22.9 million at September 30, 2010.

2011 Financial Guidance

Jazz Pharmaceuticals is providing full year 2011 financial guidance as follows:

– Total product sales

$ 232 – 245 million

– Xyrem

$ 200 – 210 million

– Luvox CR

$ 32 – 35 million

– Gross margin

greater than 90%

– R&D expenses

$ 20 – 24 million

– SG&A expenses

$ 87 – 93 million

– GAAP net income per diluted share

$ 2.22 – 2.41

– Adjusted net income per diluted share*

$ 2.70 – 2.90

* A reconciliation of GAAP net income to adjusted net income and the related per diluted share amounts is available in a table with this press release.

Display More

http://www.dailymarkets.com/st…d-full-year-2010-results/

JAZZ, Jazz Pharmaceuticals, Inc.

Hallo Zusammen, ich habe heute in meinem Kalender den Termin für Jazz gesehen und habe die Aktie daraufhin während den Handelszeiten gekauft. Die Firma ist wie Vagnum ebenfalls einmal gesagt hat, eine gute mit guten Zahlen und steigender Tendenz. Ich erlaube mir schnell Euch darauf hinzuweisen, dass neue Ratings die Aktie in der nächsten Zeit weiter in die Höhe treiben könnten.

Ich habe mal erwähnt, dass mir die Aktie mehr Wert ist als jetzt. Ein Nachkauf in den After-hours sollte man sich schon überlegen.

So, das wären schnell meine wenigen Worte. Ich arbeite gerade etwas länger und schaue hin und wieder in die Märkte hinein.

Viel Glück und Happy Trading!

JAZZ 41.25$

JAZZ neues all time high 44.05$

Jazz Pharmaceuticals, Inc. Raises FY 2011 Guidance

Quote:

Quote

Tuesday, 3 May 2011 04:00pm EDT

Jazz Pharmaceuticals, Inc. updated fiscal 2011 guidance and expects product sales to be in the range of $237-$250 million, GAAP net income per diluted share (EPS) in the range of $2.50-$2.66 and adjusted net income per diluted share in the range of $2.95-$3.10. According to Reuters Estimates, analysts on an average were expecting the Company to report revenues of $249 million and EPS of $2.91 for fiscal 2011.

JAZZ 43.75$

Jazz Pharmaceuticals And Azur Pharma Agree To Combine To Form Jazz Pharmaceuticals Plc

Quote:

Quote

– Combined company would have a diversified product portfolio, strong cash flow and expected annual revenues of more than $475 million –

– Jazz Pharmaceuticals stockholders to own slightly under 80 percent of combined entity; Azur Pharma stockholders to own slightly more than 20 percent –

– Conference call today at 4:30 PM ET to discuss transaction –

PALO ALTO, Calif. and DUBLIN, Sept. 19, 2011 /PRNewswire/ — Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) and Azur Pharma Limited today announced that the companies have agreed to combine in an all-stock transaction that creates a specialty pharmaceutical company incorporated in Ireland with a diversified portfolio of products currently marketed in the United States (US). The combined company would be named Jazz Pharmaceuticals plc.

Azur Pharma is a privately-held, profitable specialty pharmaceutical company headquartered in Dublin, Ireland with US operations in Philadelphia. The company markets ten specialty pharmaceutical products in the US in the central nervous system (CNS) and women’s health areas, with expected 2011 net sales of approximately $95 to $100 million.

“This significant transaction represents a compelling strategic fit, given our companies’ closely aligned missions of identifying and developing products that address unmet patient needs and can be efficiently marketed through a specialty commercial infrastructure,” said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. ”Our combined organizations would have a diverse portfolio of products and an international platform, paving the way for long term growth that builds on our current strengths. We look forward to working with our colleagues at Azur Pharma to join our two companies into one that is even stronger, creating value for our stockholders while serving more patients.”

Seamus Mulligan, chairman and chief executive officer of Azur Pharma added, “This combination brings together two successful businesses and cultures in a larger company better situated to compete in the specialty pharmaceutical sector. The combined company would have greater operational and financial resources to enable its strategy to acquire and develop important specialty pharmaceutical products.”

The combined company is expected to have a diversified revenue base from 12 products currently marketed in the US in the CNS and women’s health areas. These include Jazz Pharmaceuticals’ currently marketed products, Xyrem® (indicated to treat the two key symptoms of narcolepsy) and Luvox CR® (indicated to treat obsessive compulsive disorder), and the Azur Pharma marketed product portfolio which includes Prialt® (indicated for refractory severe chronic pain), FazaClo® (indicated for treatment resistant schizophrenia), two additional CNS products and a portfolio of women’s health products led by Elestrin® (for vasomotor symptoms associated with menopause). The combined company would also have a pipeline of lower-risk development programs including line extensions for the clozapine franchise and certain branded women’s health products. Full prescribing information about each product is available on its website.

Financial Projections

The combined company, Jazz Pharmaceuticals plc, is expected to have revenues of more than $475 million and generate cash of more than $200 million in the first 12 months following closing. The company would also have a strong balance sheet, with no debt and approximately $250 million in cash expected at closing.

Transaction Terms

Upon completion of the merger, shareholders of Jazz Pharmaceuticals, Inc. would own slightly under 80 percent of Jazz Pharmaceuticals plc, and Azur Pharma shareholders would own slightly over 20 percent. Shareholders of Jazz Pharmaceuticals, Inc. would receive one ordinary share of Jazz Pharmaceuticals plc in exchange for each share of Jazz Pharmaceuticals, Inc. common stock they own at closing. The combined company is expected to have a capitalization of approximately 60 million fully diluted shares. Jazz Pharmaceuticals plc would be a Securities and Exchange Commission reporting company, and its shares would trade on NASDAQ. The transaction will be taxable to the Jazz Pharmaceuticals, Inc. US shareholders.

Leadership

Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, Inc., would be Chairman and CEO of Jazz Pharmaceuticals plc, and current officers of Jazz Pharmaceuticals, Inc. would be officers of the combined company. Seamus Mulligan, Chairman and CEO of Azur Pharma, would be a member of the board the directors of Jazz Pharmaceuticals plc along with the current directors of Jazz Pharmaceuticals, Inc. He would also serve as Chief Business Officer, International Business Development, for Jazz Pharmaceuticals plc. Other Azur Pharma executives would join the executive team of Jazz Pharmaceuticals, Inc. in important leadership and management roles for the combined company.

Approvals

The transaction, which has been approved by the boards of directors of both companies, is subject to approvals by Jazz Pharmaceuticals, Inc. and the satisfaction of customary closing conditions and regulatory approvals, including antitrust approval in the US. The transaction is expected to close during the first quarter of 2012.

Certain affiliates of Jazz Pharmaceuticals, Inc. who hold approximately 43 percent of the outstanding shares of common stock of Jazz Pharmaceuticals, Inc., and certain shareholders of Azur Pharma who hold approximately 99 percent of the outstanding ordinary shares of Azur Pharma, have agreed to vote in favor of and take necessary actions on matters related to the transaction described in this press release.

Advisors

Jazz Pharmaceuticals’ financial advisor for the transaction is J.P. Morgan Securities LLC, and its legal advisors are Cooley LLP, Baker & McKenzie and A&L Goodbody (Dublin).

Azur Pharma’s financial advisor for the transaction is Lazard and its legal advisors are Mayer Brown LLP, McCann FitzGerald and ByrneWallace (Dublin).

Conference Call Today at 4:30 PM ET

Jazz Pharmaceuticals will host a conference call and live audio webcast today at 1:30 p.m. PT/4:30 p.m. ET to discuss this transaction and related matters. Management representatives of Jazz Pharmaceuticals and Azur Pharma will participate. The live webcast may be accessed from the Investors section of the company’s website at http://www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing 1-866-277-1184 in the US, or 1-617-597-5360 outside the US, and entering passcode 45317826.

An archived version of the webcast will be available for at least one week on the investors section of the Jazz Pharmaceuticals website at http://www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information see http://www.jazzpharmaceuticals.com.

About Azur Pharma

Azur Pharma Limited is a privately held pharmaceutical company dedicated to enhancing patients’ lives by developing and marketing pharmaceutical products in specialist therapeutic areas. Azur Pharma’s strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development and approved pharmaceutical products. The company’s website is available at http://www.azurpharma.com.

Display More

JAZZ 41.52$

hat zwar nix mit der aktie zu tun aber trotzdem hörenswert.

4

JAZZ 55$

Jazz Pharmaceuticals PLC : Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders

03/05/2013| 09:05am US/Eastern

DUBLIN, March 5, 2013 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the pricing of a previously announced underwritten public offering of 5,375,000 of its ordinary shares held by certain of its existing shareholders, offered at a price to the public of $58.50 per share. Jazz Pharmaceuticals will not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering, and its total number of ordinary shares outstanding will not change as a result of the offering. The offering is expected to close on or about March 8, 2013, subject to customary closing conditions.

Barclays Capital Inc. is acting as sole book-running manager and underwriter in this offering.

A registration statement relating to the shares described above was previously filed with and has become effective by rule of the Securities and Exchange Commission ("SEC"). A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the final prospectus supplement and related prospectus, when available, may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at 1-888-603-5847, or by email at Barclaysprospectus@broadridge.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the shares in any state or other jurisdiction which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, FazaClo® (clozapine, USP) HD, FazaClo LD, and Luvox CR® (fluvoxamine maleate). Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the public offering of ordinary shares of Jazz Pharmaceuticals. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the public offering. Additional risks and uncertainties relating to the public offering, Jazz Pharmaceuticals and its business can be found under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including in its Annual Report on Form 10-K for the year ended December 31, 2012. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

SOURCE Jazz Pharmaceuticals plc

http://bit.ly/W8tryP

vagnum hat am 30.09.2011 - 22:59 folgendes geschrieben:

Quote

hat zwar nix mit der aktie zu tun aber trotzdem hörenswert. smiley

http://youtu.be/DBjYOLVy5kI

have fun.

4

YEEES!

JAZZ 55$

[Blocked Image: http://finviz.com/chart.ashx?t=JAZZ&ty=c&ta=1&p=d&s=l]

Wie weit noch !!!!

Hallo

Ich könnte ko....!

Ich beobachte die Aktie schon seit 10 Dollar und dachte immer jetzt korrigiert sie dann Mal aber denkste die geht

Voll durch.

Sind noch paar dabei? Und lohnt sich noch ein Einstieg? Was meint Ihr?

Gruss Köbeler

good 11am from India.

and a wonder full

Pichikara

Dostana – Khabar Nahi

Mein bestes Investment ever. Und das dank den Postings von Vagnum hier. Vielen Dank dafür!

Habe noch nie eine Aktie erlebt, die dermassen wie eine Rakete abgeht...

LG,

rascalinho